Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 23 November 2007:
Vol. 318. no. 5854, pp. 1296 - 1299
DOI: 10.1126/science.1149726
Prev | Table of Contents | Next

Reports

Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell Niches

Agnieszka Czechowicz, Daniel Kraft, Irving L. Weissman,*{dagger} Deepta Bhattacharya{dagger}

Upon intravenous transplantation, hematopoietic stem cells (HSCs) can home to specialized niches, yet most HSCs fail to engraft unless recipients are subjected to toxic preconditioning. We provide evidence that, aside from immune barriers, donor HSC engraftment is restricted by occupancy of appropriate niches by host HSCs. Administration of ACK2, an antibody that blocks c-kit function, led to the transient removal of >98% of endogenous HSCs in immunodeficient mice. Subsequent transplantation of these mice with donor HSCs led to chimerism levels of up to 90%. Extrapolation of these methods to humans may enable mild but effective conditioning regimens for transplantation.

Institute of Stem Cell Biology and Regenerative Medicine, Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.

{dagger} These authors contributed equally to this work.

* To whom correspondence should be addressed. E-mail: irv{at}stanford.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement.
Z. Wang, G. Li, W. Tse, and K. D. Bunting (2009)
Blood 113, 4856-4865
   Abstract »    Full Text »    PDF »
Successful Low-Risk Hematopoietic Cell Therapy in a Mouse Model of Type 1 Gaucher Disease.
I. B. Enquist, E. Nilsson, J.-E. Mansson, M. Ehinger, J. Richter, and S. Karlsson (2009)
Stem Cells 27, 744-752
   Abstract »    Full Text »    PDF »
Gene Therapy Fulfilling Its Promise.
D. B. Kohn and F. Candotti (2009)
N. Engl. J. Med. 360, 518-521
   Full Text »    PDF »
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
C. Louvet, G. L. Szot, J. Lang, M. R. Lee, N. Martinier, G. Bollag, S. Zhu, A. Weiss, and J. A. Bluestone (2008)
PNAS 105, 18895-18900
   Abstract »    Full Text »    PDF »
The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases.
I. L. Weissman and J. A. Shizuru (2008)
Blood 112, 3543-3553
   Abstract »    Full Text »    PDF »
Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell.
Y. J. Chung, C. W. Choi, C. Slape, T. Fry, and P. D. Aplan (2008)
PNAS 105, 14088-14093
   Abstract »    Full Text »    PDF »
FIP1L1/PDGFR{alpha} synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome.
Y. Yamada, A. Sanchez-Aguilera, E. B. Brandt, M. McBride, N. J. H. Al-Moamen, F. D. Finkelman, D. A. Williams, J. A. Cancelas, and M. E. Rothenberg (2008)
Blood 112, 2500-2507
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)